Pietrasz et al. reported that 41.3% of patients with advanced PDA had detectable ctDNA KRAS mutation by NGS and droplet-based dPCR in microfluidics with a high concordance between the two technics [38]. The gene discussed is KRAS; the disease is Patent ductus arteriosus.